June 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips' current issued share capital amounts to EUR 187,987,876.80 representing 939,939,384 common shares. More information is available here. Ben Zwirs Philips External Relations ...

Philips expects 2024 comparable sales growth for the underlined segment in the band of 3-5%. The consensus mark for 2024 earnings is pegged at $1.54 per share, indicating an increase of 14.1% year over year. The figure has moved upward by 0.7% in the past 30 days. Zacks Rank & Stocks to Consider Some better-ranked stocks in the broader medical market sector are DaVita (DVA) , ICON (ICLR) and Encompass Health (EHC) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zac ...

June 18, 2024 Healthcare leaders indicate automation is crucial in addressing staff shortages, but staff remain skeptical Interest in Generative AI grows, with majority of health leaders investing in, or planning to invest in AI technologies to help reduce delays in patient care Amsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of its Future Health Index 2024 report: Better care for more people. Launched at HLTH Europe, the ni ...

Amsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of its Future Health Index 2024 report: Better care for more people. Launched at HLTH Europe, the ninth annual FHI global report shows that healthcare leaders are turning to virtual care and AI-enabled innovation to address pressure due to workforce shortages, financial burdens, and growing demand. June 18, 2024 Healthcare leaders indicate automation is crucial in addressing st ...

June 17, 2024 Increased control and efficiency with automated workflows In independent hands-on usability studies of clinicians from the US and EU with the Zenition 90 Motorized in simulated environments; 100% of users said that with the Table Side Operator, they have complete control over C-arm movements [2] and 97% report that workflow features such as Automatic Vascular Outlining will help save time during procedures [3]. [1]Also available in 15 kW [2] Results obtained during claims substantiation study ...

June 17, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – Zenition 90 Motorized, designed to help clinicians deliver high-quality care to more patients. Philips is partnering with its customers to improve productivity. The new mobile C-arm with expanded capabilities is designed to meet complex vascular needs, but also a range of clinical procedures such as cardia ...

In this regard, Philips' recent launch of the Duo Venous Stent System in a bid to boost its Image-Guided Therapy portfolio remains noteworthy. Expanding Portfolio & Partner Base Aid Diagnosis & Treatment Similarly, PHG also unveiled HealthSuite Imaging, an AI-enabled cloud-based Picture Archiving and Communication System, which offers high-speed remote diagnostic reading, integrated reporting and AIpowered workflow orchestration, enhancing operational efficiency and patient care. Bottom Line The strengtheni ...

The 12-month effectiveness endpoint for primary patency reached 90.2%, which exceeded the performance target goal of 77.3%. The 12-month primary safety endpoint of 98.7% also exceeded the corresponding performance goal of 89%. In addition, quality of life and venous functional assessments that were performed in the VIVID study – including Clinical-Etiology-Anatomy-Pathophysiology (CEAP), Venous Clinical Severity Score (VCSS), Villalta, EQ-5D-3L and VEINES scores – showed sustained improvements compared to b ...

Philips' (PHG) shares have gained 17.6% in the year-to-date period, outperforming the Zacks Medical sector's growth of 4.3%. The company is benefiting from strong momentum in the Diagnosis & Treatment segment on the back of its strengthening Precision Diagnosis portfolio powered by artificial intelligence (AI). The company's latest launch of an AI-enabled cardiovascular ultrasound platform testifies to the aforesaid fact. This FDA 510(k) cleared AI platform combines Philips' EPIQ CVx and Affiniti CVx ultras ...

June 4, 2024 New FDA-cleared AI-enabled applications include the industry's first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds First fully automated 3D quantification of mitral regurgitation (MR) volumes* designed to provide reproducible, efficient analysis helps clinicians make better-informed decisions for patients with heart valve disease Amsterdam, the Netherlands – Roya ...